4. Conclusion
The spectacular success of fecal transplantation in the treatment of recurrent Clostridium difficile infections has led to this treatment being considered for many other mucosal and skin pathologies in which the microbiota plays a major role. This very recent work, carried out on a small number of patients or, above all, animals, is not yet sufficiently conclusive, especially as it has just been shown that in "germ-free" mice, animals widely used in these trials, human bacteria recognized as anti-inflammatory, such as Faecalibacterium and Bifidobacterium, are not transferable to them. What's more, cytokines and chemokines have very different plasma levels in humans and in these animals, which makes it difficult to predict any immunological effect in humans
Exclusive to subscribers. 97% yet to be discovered!
You do not have access to this resource.
Click here to request your free trial access!
Already subscribed? Log in!
The Ultimate Scientific and Technical Reference
This article is included in
Healthcare technologies
This offer includes:
Knowledge Base
Updated and enriched with articles validated by our scientific committees
Services
A set of exclusive tools to complement the resources
Practical Path
Operational and didactic, to guarantee the acquisition of transversal skills
Doc & Quiz
Interactive articles with quizzes, for constructive reading
Conclusion
Bibliography
Bibliography
Firms specializing in fecal transplant preparations
In France
MAAT Pharma in Lyon [email protected]
In the USA
Rebiotix in Roseville Minnesota [email protected]
Exclusive to subscribers. 97% yet to be discovered!
You do not have access to this resource.
Click here to request your free trial access!
Already subscribed? Log in!
The Ultimate Scientific and Technical Reference